MECHANISM OF ACTION

The only intranasal needle-free flu vaccine with 3-way immune response1,2*

The only intranasal needle-free flu vaccine with 3-way immune response1,2*

FLUMIST is uniquely designed to start working at the typical site of viral entry and infection—the nose—and stimulate the immune system's production of systemic lgG, mucosal IgA, and T cells1-9

Needle-Free Flu Vaccine with 3-Way Immune ResponseNeedle-Free Flu Vaccine with 3-Way Immune Response

*While the mechanism of action conferring protection is not fully understood, serum antibodies, mucosal antibodies, and influenza-specific T cells may play a role.1

Mucosal immunity may be an important factor in developing an immune response1,10

LAIV=live attenuated influenza vaccine;

IgG=immunoglobulin G;

IgA=immunoglobulin A.

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.